Publicaciones en las que colabora con Iñaki Etxeberria Ruesta (35)

2023

  1. Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8+ T cells eradicates peritoneal metastases in mouse models

    Oncoimmunology, Vol. 12, Núm. 1, pp. 2147317

  2. Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity

    Cancer immunology research, Vol. 11, Núm. 2, pp. 184-198

  3. Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma

    Cell Reports Medicine, Vol. 4, Núm. 4

  4. mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy

    Cell Reports Medicine, Vol. 4, Núm. 3

2022

  1. A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα and IL-1β

    Cancer Discovery, Vol. 12, Núm. 9, pp. 2140-2157

2021

  1. Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 26

  2. CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation

    Nature Communications, Vol. 12, Núm. 1

2020

  1. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    Immunity, Vol. 52, Núm. 5, pp. 856-871.e8

  2. Cellular cytotoxicity is a form of immunogenic cell death

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1

  3. Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms

    Cellular and Molecular Immunology, Vol. 17, Núm. 6, pp. 576-586

  4. Exploiting TCR Recognition of Shared Hotspot Oncogene-encoded Neoantigens

    Clinical Cancer Research, Vol. 26, Núm. 6, pp. 1203-1204

  5. Human CD8 T cells are susceptible to TNF-mediated activation-induced cell death

    Theranostics, Vol. 10, Núm. 10, pp. 4481-4489

  6. New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis

    ESMO open, Vol. 4, pp. e000733

  7. Repurposing infectious disease vaccines for intratumoral immunotherapy

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1

  8. Repurposing the yellow fever vaccine for intratumoral immunotherapy

    EMBO Molecular Medicine, Vol. 12, Núm. 1

2019

  1. Cytokines in clinical cancer immunotherapy

    British Journal of Cancer, Vol. 120, Núm. 1, pp. 6-15

  2. Immunotherapeutic effects of intratumoral nanoplexed poly I:C

    Journal for ImmunoTherapy of Cancer, Vol. 7, Núm. 1

  3. Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells

    Cancer cell, Vol. 36, Núm. 6, pp. 613-629

  4. Metabolic consequences of T-cell costimulation in anticancer immunity

    Cancer Immunology Research, Vol. 7, Núm. 10, pp. 1664-1669

  5. TGFb blockade enhances radiotherapy abscopal efficacy effects in combination with anti-PD1 and anti-CD137 immunostimulatory monoclonal antibodies

    Molecular Cancer Therapeutics, Vol. 18, Núm. 3, pp. 621-631